MD, MBA (NYU-Stern, Finance specialization). Founder: Vasuda Healthcare Analytics, premium research service covering emerging biotech/ pharma companies. Licensed Investment Advisor.
Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform.
Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
Founder, managing principal of Vasuda Capital Management, healthcare focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts. The firm also operates a private investment partnership, Vasuda Life Sciences Fund.
Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
I am retired, I live along the Columbia River in the area called "The Gorge". I bought my first mutual fund when I was 24 (1962). I mainly trade options now but have a few dividend stocks that I dont write calls on.
SmartStops.net is an online service dedicated to helping investors of all levels improve their risk management capabilities and thus better protect their profits and minimize their losses. Buying decisions are made on a risk / reward basis. Unfortunately, the past measurements of "risk" have proven insufficient. SmartStops.net optimized methodology provides a continually adjusting measurement depending upon individual stock or ETF behavior combined with overall macro market trend behavior. The service provides effective, easy-to-use risk monitoring and alert services designed to help investors identify periods of above normal risk and take timely action to protect assets, improve returns and achieve peace of mind.
For more information on how to leverage SmartStops to achieve your investment goals, visit us at http://www.smartstops.net.
As director of research at Portfolio123, I have long specialized in rules/factor-based equity investing strategies of the sort characterized as “Smart Alpha” in the July 2014 Journal of Portfolio Management. In addition, I formerly managed a high-yield fixed-income fund and conducted research involving quantitative asset allocation strategies such as are at the foundation of what today has come to be known as Robo Advising. I formerly edited the the Forbes Low Priced Stock Report, and served as an assistant research director at Value Line. I have long had a passion for investor education, which has resulted in my having conducted numerous seminars on stock selection and analysis, and the authoring of two books: Screening The Market and The Value Connection.
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
I am an individual investor currently swing trading volatility ETNs (XIV and VXX). I am developing strategies for timing trades and backtesting using excel.
Contango is my friend.
My handle on twitter is @ContangoMojo
Cited by Barron's as one of the top financial websites to visit on the weekend, Financial Sense (www.financialsense.com) provides educational resources to the broad public audience through a daily podcast, editorials, current news and resource links on salient financial market issues. Begun in 1985 as a local talk radio program, Financial Sense Newshour (www.financialsense.com/financial-sense-newshour) is a weekly webcast with host Jim Puplava and top financial thinkers. Writing staff of Financial Sense includes: Jim Puplava, Chris Puplava, Ryan Puplava, and Cris Sheridan.
Seeking alpha has been one of the "go-to" sites for the investors in our family. We would like to strike a perfect balance between short term trading and long term investing, hence the name "Tradevestor".Good luck investing. In the interest of full disclosure, this is a group account handled by Father and Son. The Father was a trader for quite a few years years with mixed returns, while the son started out a few years ago with DGI and has slowly convinced the Patriarch towards investing rather than trading.
Disclaimer: Please do your own due diligence before buying or selling any stock. Ideas and thoughts presented in the articles are not professional recommendations.
I am the founder of the Braeburn Group of independent AAPL analysts and author of the Posts At Eventide web presence.
The objective of my work is to benefit readers seeking to understand Apple's financial performance and to provide a repository of information and analysis at my web presence for other independent AAPL analysts preparing quarterly estimates and share price forecasts.
In addition to following Apple, I maintain a keen interest in the personal technology product markets and follow publicly traded enterprises offering technology products and services to consumers.
Robert Paul Leitao
Author of the critically acclaimed book, "Taking Charge With Value Investing (McGraw-Hill, 2013)" and the premium subscription service "Tipping The Scale" (as seen below). An analyst that ranks in the top 4% on both tipranks.com and Motley Fool CAPS for stock picking performance.
Tipping the Scale members gain access to the TTS Portfolio Tracker. Here, members see what I am buying and selling the minute it happens, along with what I have owned, bought, and sold historically. These are just a few of the features on the TTS Portfolio Tracker.
Tipping The Scale is an equity research platform that uses a numeric scale instead of the traditional "Buy, Hold, Sell" to identify the best investment opportunities in the market. Stock coverage is determined by market catalyst, and every company goes through a vigorous test in 10 different categories. The higher the total score, the bigger the upside. In addition, Tipping the Scale also provides a number of portfolio strategies to hedge the volatility of the market and protect from downside.
Check out my instablog for more information on the popular research service Tipping the Scale, including performance information, benefits, and how it all works.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
Rona Fried, Ph.D., is editor of Progressive Investor and CEO of SustainableBusiness.com. Known for her wide-ranging, deep knowledge of sustainable business, she speaks and writes on topics related to green business, green jobs and green investing.
She writes the "Investing in Clean Energy" column for Solar Today, and serves on numerous Advisory Boards: the WilderHill Clean Energy Index (ECO), which manages the bellweather clean energy ETF (PBW), the WilderHill New Energy Global Innovation Index (NEX), which tracks the clean energy sector worldwide (NEX), and PowerShares Global Progressive Transportation Portfolio (PTRP).
Bart King is News Editor for SustainableBusiness.com, producing daily news on green business and on green investing, as well as producing our Green Week in Review podcast.
Founder of Disruptive Tech Research – a technology research and advisory firm serving the investment management community.
We provide registered investment professionals and qualified firms with independent, targeted research to support the generation of investment ideas.
We focus on patent-filing activity to identify the most promising disruptive technology trends early. Then, we employ an original, bottom-up fundamental research approach to uncover micro- and small-cap ideas that are underfollowed, underappreciated and undervalued.
Our mission is to provide clients with differentiated, actionable and thorough fundamental research at a cost effective price.
We’re 100% independent. That means absolutely no pay-to-play arrangements, no hidden agendas and no hype. Just solid research. And yes, we eat our own cooking.
I started my investment career at Morgan Stanley, where I helped direct over $1 billion in in institutional capital. After growing bored with the monotony of asset allocation studies, investment policy statements, manager searches and evaluations, and Retirement Plan Service Provider RFPs (among other things), I left and co-founded Wall Street Daily, which quickly became one of the web’s largest financial publishers with a daily circulation of more than 700,000 readers.
In 2014, I founded Disruptive Tech Research to pursue my investing passion, and fill the void in the market for high-quality, 100% independent research on disruptive technologies.
I have been fortunate to appear regularly on CNBC’s Closing Bell, as well as be mentioned in other media outlets, including in The Wall Street Journal, The New York Times, Morningstar and MarketWatch. I earned my MBA from the Crummer Graduate School of Business at Rollins College, which is also where I met my beautiful wife.
Pro Deo, Pro Familia, Pro Patria
I worked for many years in management in the health care industry in the UK, in Bermuda, and for the last 20 years in Florida. The day I turned 59 1/2 I just got out of bed and decided I didn't want to work any more and that I would just take my various pensions from different countries, such as they were, roll them all into one big IRA, and just see if I could live by my wits. My investment objective is, therefore, to make enough so that I never have to work again, although it would be easy for me to do so if I wanted.
I could probably get by very well with a 10% annual yield on my capital, but of course more is more and much more is much more.
When I started out investing in stocks, I really didn't know what I was doing, but I had the occasional bit of luck, like investing every penny I had in BP in the summer of 2010, just when it couldn't go any lower. And it didn't. Then again I staked every dime I had on out of the money options on a drug that had a PDUFA date in January 2011. It was approved. Phew! But I was a nervous wreck and figured there had to be a better way.
Then about a year ago I started to study the whole business of options strategies, got myself a few books, and found out that you could sell options as well as buy them. This was a bit of a revelation, to say the least, because I had noticed that whenever I thought a stock would go up, it went down,and when I thought it would go down, it usually went up, but by selling options you could let other people's optimism work for you.
Then I found out about volatility. I had always known that the whole game was rigged, but now I began to understand how and why
I'm hoping that with some blog posts or articles here I can inform others about some of the things that I have learned in my time as a full time investor and personal hedge fund manager (O.K., layabout) so that they can avoid some basic errors, and I hope to attract enough criticism to be able to learn from those who know much more than me.
I have been trading max pain type data since 2007 after noting odd trading patterns centered around options expiry. I am a more conservative trader/investor and only take high probability trades. I prefer to know where stocks won’t be rather than guess where they will be. Trading with this mind set gives you 80% plus probability of being correct.
I have always been a stock market enthusiast. My formal training is that of informal. I am self taught, soaking up as much knowledge as can be absorbed. I love the financial industry and would work for free. I am a fundamental investor at heart and like crunching the numbers. I picked up on Max Pain theory and use option data as a main thesis in taking my positions.
In the beginning; when studying Max Pain I was truly amazed at the power it had in pulling or pushing AAPL around. I have seen the stock drop 5% out of nowhere with no news. The only news would be it was the 3rd Friday of the month. I then picked up on hitting the Max Pain strike was about 50/50 odds. Max Pain would give you a tell on what direction AAPL would start heading for expiry. I started to build a strategy from my studies. Using the Max Pain strike is not really tradable, good to know, but not tradable. So I started to study open interest (OI) and its affect on AAPL. Long story short, I have altered the original Max Pain theory and morphed it into what my own studies have concluded. I call this OI/Max Pain, it uses open interest and a range. This way it is tradable as I now have a high probability range. It doesn’t stop there, using OI will tell you so much more. How a stock reacts at each strike depending on the amount of OI is a major tell.
Conclusion: When using open interest you can accomplish multiple things. We can use it for OI/Max Pain when AAPL is stuck in a range and we can use it for catching breakouts, breakdowns, buy and sell points. Enjoy.
I want to give a special thanks to some of my early influences: Turley Muller, Andy Zaky and Jason Schwarz. I thank Philip Elmer-Dewitt for his coverage on AAPL and letting us have a voice, Horace Dediu for his tireless studies and anyone attached to the AAPL community.
Follow me on https://twitter.com/#!/RobertWeinstein
Owner of 1 Reason Insurance, a full-line insurance agency licensed in Wisconsin and Minnesota, and 1 Reason Real Estate, licensed in Wisconsin. http;//1reason.com
Let's connect on Linkedin http://www.linkedin.com/pub/robert-weinstein/12/129/651
Google + Profile https://plus.google.com/110309851050284795454
Contributor to StockSaints' weekly Options Investing newsletter
Robert Weinstein is an active trader focusing on the psychological importance of risk mitigation, emotion and financial behavior of market participants. Robert co-founded the investing blog StockSaints, where he writes a journal about his trading activity and experiences.
SoundView conducts research and analysis on emerging technologies and companies for investors. The director of research, Kris Tuttle, has over 32 years of hands-on work in technology, business and markets. Early in his career Kris was an AI researcher at Carnegie Mellon University and spent 8 years with IBM developing and implementing new "bleeding edge" technologies in multiple industries.
Later he obtained an MBA in finance and moved into institutional sales at UBS and then equity research at SoundView Technology Group where he eventually came to run research there before being acquired by Charles Schwab in 2003. While at SoundView his name was closely associated with companies like Atria Software, Rational Software, BEA Systems, Business Objects, and Netscape and he was recognized by institutional investors as the "most informed, independent and money-making analyst in the market."
Kris founded his own firm in April of 2005 and acquired the SoundView trademarks in 2011 under which the the firm now operates. Parts of the predecessor brand "Research 2.0" are still found online.
I became interested in the stock market at a young age, and asked for and received an account at Scottrade for my 15th birthday. I have been fascinated by the markets and investing ever since, and have been constantly trading in them and trying to learn better ways of managing my accounts.
I also recently created a blog about these things, where I share my knowledge and ideas with others: www.InvestingByWali.com
Ed Silverman is the founding editor of Pharmalot and a prize-winning journalist who has covered the pharmaceutical industry for the past 15 years for The Star-Ledger of New Jersey, The Pink Sheet and, currently, as an editor-at-large for Med Ad News and R&D Directions.
Efsinvestment.com website offers simple do-it-yourself type of investment ideas. You can download excel files that can easily calculate the Fair Value of a stock, along with O-Metrix score and Margin of Safety.
Investment philosophy is to first determine the maximum loss, and invest accordingly. Like many value investors, we prefer to invest in stocks with the highest dividend yields, and highest EPS growth potentials. Telecommunication and energy stocks in emerging markets are among the favorites.
Seeking Alpha offers a great opportunity to become a part of a strong finance network. Based on extensive quantitative analysis, in any market, going short is risky. Statistical analysis shows that technical indicators work only if they are strong enough to convince the majority of the investors. Do not buy a stock at the top, do not sell a stock at the dip.
Tom, a native of Berwyn, IL, has been interested in stocks, bonds and real estate for over forty years. A classically-trained woodwind musician and retired High School Principal, he holds two master's degrees and blogs.
Mr. Smicklas values a conservative, diversified approach towards investing utilizing varied income streams, always sensitive to of the march of political and economic trends worldwide.
Tom knows that in the investment world there is no substitute for experience, with failure as well as success.
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
At Investment Underground, our editors are disciplined, independent journalists who dig into technology, commodities, and stock market news to break the stories that matter. Our active approach to journalism spans analysis and interviews with noteworthy leaders to uncover real news that affects business right now.
Most notably, our insights predicted the departure of Avon CEO, Andrea Jung, and Warren Buffett’s purchase of his first technology stock in over forty years at Berkshire Hathaway.
Our work appears in Google News, Seeking Alpha, Motley Fool, Morningstar, Vatalyst, Value Walk, and Guru Focus, among others.
We're in the midst of the greatest investing boom in almost 60 years. And rest assured - this boom is not about to end anytime soon.
You see, the flattening of the world continues to spawn new markets worth trillions of dollars; new customers that measure in the billions; an insatiable global demand for basic resources that's growing exponentially ; and a technological revolution even in the most distant markets on the planet.
And Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. In fact, we believe this is where the only real fortunes will be made in the months and years to come.
The bottom line is this: With U.S. influence slipping, and the dollar declining as well, investors who think too narrowly about this transformation will face years of meager returns. But those who embrace this new global reality can make themselves very wealthy.
Please visit us at MoneyMorning.com
Disclaimer: Money Morning and Stansberry & Associates Investment Research are separate companies, and entirely distinct. Their only common thread is a shared parent company, Agora Inc. Agora Inc. was named in the suit by the SEC and was exonerated by the court, and thus dropped from the case. Stansberry & Associates was found civilly liable for a matter that dealt with one writer’s report on a company. The action was not a criminal matter. The case is still on appeal, and no final decision has been made.
Adam Gefvert is the head researcher for White Diamond Research, a research firm for hedge funds and high net worth individuals. Primarily a short seller, he has saved investors millions of dollars by exposing highly overvalued small cap stocks. He has a 90%+ success rate with his Seeking Alpha short ideas. He specializes in technology, energy, and biotech stocks, because those are the sectors with the greatest valuation inefficiencies.
You can follow Adam on twitter @shiningboy
China has become the #2 pharmaceutical market years ahead of projections and continues to be the fastest growing market in the world. China is $50 billion dollars a year into life science and healthcare development through over 160 government funding programs. VC investment, M&A transactions and cross-border partnering deals in China were all up significantly in 2012.
ChinaBio® Today focuses exclusively on the rapidly evolving life science industry in China, including biotech, pharma, medical device, diagnostics, services and tools. From our offices in Shanghai and San Diego, our industry analysts provide daily news, commentary and analysis on public and private China life science companies, as well as events and global issues affecting the China market.
Visit: ChinaBio Today (http://www.chinabiotoday.com)
ChinaBio LLC (http://www.chinabiollc.com)